Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...
Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk ...
HER-2 targeted antibody-drug conjugate monotherapy has demonstrated efficacy in the post-chemotherapy setting for ...
On busy days, you may not feel you have the time to sit on a toilet and wait for your bladder to empty, so you “power pee” — you bear down to expel urine faster. “Power peeing is a really common habit ...
Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...
EG110A received FDA fast track designation to treat neurogenic detrusor overactivity, a bladder issue common in MS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback